Eli Lilly & (id:8473 LLY)
767.76 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 5:43:13 AM)
Exchange closed, opens in 3 hours 46 minutes
About Eli Lilly &
Market Capitalization 692.82B
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Headquarters (address) |
Lilly Corporate Center Indianapolis 46285 IN United States |
Phone | 317 276 2000 |
Website | https://www.lilly.com |
Employees | 43K |
Sector | Healthcare |
Industry | Drug Manufacturers General |
Ticker | LLY |
Exchange | New York Stock Exchange |
Currency | USD |
52 week range | 567.64 - 972.53 |
Market Capitalization | 692.82B |
Dividend yield forward | 3.00 % |
Dividend yield forward United States (ID:6, base:1851) | 4.34 % |
P/E trailing | 82.66 |
P/E forward | 34.00 |
Price/Sale | 16.95 |
Price/Book | 48.68 |
Beta | 3.00 |
EPS | 9.32 |
EPS United States (ID:6, base:3378) | 25.00 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Eli Lilly & has raised their dividend 3.00 years in a row. This is below the 42108.402200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Eli Lilly & has raised their dividend 4.63 years in a row. This is below the 24.027400 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Eli Lilly & has raised their dividend 8.54 years in a row. This is below the 12.562000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Eli Lilly & has raised their dividend 5.63 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Eli Lilly & has raised their dividend 54.20 years in a row. This is below the 148.441400 year average in the 'Drug Manufacturers General' industry
Self funded year
Eli Lilly & years needed to self fund. This is below the 34.103116 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Eli Lilly & has raised their dividend 3.00 years in a row. This is below the 42108.402200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Eli Lilly & has raised their dividend 4.63 years in a row. This is below the 24.027400 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Eli Lilly & has raised their dividend 8.54 years in a row. This is below the 12.562000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Eli Lilly & has raised their dividend 5.63 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Eli Lilly & has raised their dividend 54.20 years in a row. This is below the 148.441400 year average in the 'Drug Manufacturers General' industry
Self funded year
Eli Lilly & years needed to self fund. This is below the 34.103116 year average in the 'Drug Manufacturers General' industry